Drug
Eravacycline clinical trials
Also written TP-434.
- studies test it
- 14
- open now
- 5
- in phase 3
- 5
- first study started
- 2011
Keep track of what changes. Save the eravacycline studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Brand
Development codes
Combined with it in one product
Studies by the year they started
14 studies that test it; most in 2013 (3)
| Year | Studies |
|---|---|
| 2011 | 1 |
| 2012 | 1 |
| 2013 | 3 |
| 2014 | 1 |
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 1 |
| 2024 | 1 |
| 2025 | 3 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 4
- Phase 2
- 3
- Phase 3
- 5
- Phase 4
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 10 · Other 4
Tetraphase Pharmaceuticals, Inc. (9) · IRCCS Azienda Ospedaliero-Universitaria di Bologna (1) · Tetraphase Pharmaceuticals, Inc (1) · West Virginia University (1) · Clinical Hospital Centre Zagreb (1) · National University of Singapore (1)
Often tested with
Tested in the same studies.
Avibactam, ceftazidime drug combination (2) · Meropenem and vaborbactam (2) · Cefiderocol (2) · Aztreonam (2) · Tigecycline (2) · Fosfomycin (2) · Sulbactam (2) · Imipenem (1)
Studies
Open first, then newest update. How each study uses eravacycline is read from its arms, and is right about nine times in ten.
Testing it · 14
- Targeted Versus Standard Peri-operative Antibiotic Prophylaxis in Patients Colonized With Carbapenemase Producing Enterobacterales Undergoing Liver TransplantationNot yet recruitingPhase 3IRCCS Azienda Ospedaliero-Universitaria di BolognaNCT07759453Written as Eravacycline
- A Study to Evaluate the Safety and Tolerability of Eravacycline in Pediatric Patients Aged 8 to 17 With Complicated Intra-abdominal Infections (cIAI)RecruitingPhase 2Tetraphase Pharmaceuticals, IncNCT06794541Written as IV Eravacycline 2mg/kg
- Prospective Evaluation of Xerava Prophylaxis in Hematological Malignancy Patients With Prolonged NeutropeniaRecruitingPhase 2West Virginia UniversityNCT05537896Written as Eravacycline
- Therapeutic Options for CRABRecruitingPhase 4Clinical Hospital Centre ZagrebNCT06440304Written as Eravacycline
- Optimising TREATment for Severe Gram-Negative Bacterial InfectionsRecruitingPhase 4National University of SingaporeNCT07004049Written as Colistin/Polymyxin B + Tigecycline/Eravacycline
- Efficacy and Safety Study of Eravacycline Compared With Levofloxacin in Complicated Urinary Tract InfectionsCompletedPhase 3Tetraphase Pharmaceuticals, Inc.NCT01978938Written as Eravacycline
- Efficacy and Safety Study of Eravacycline Compared With Ertapenem in Complicated Intra-abdominal InfectionsCompletedPhase 3Tetraphase Pharmaceuticals, Inc.NCT01844856Written as Eravacycline
- Efficacy and Safety Study of Eravacycline Compared With Meropenem in Complicated Intra-abdominal InfectionsCompletedPhase 3Tetraphase Pharmaceuticals, Inc.NCT02784704Written as Eravacycline
- Efficacy and Safety Study of Eravacycline Compared With Ertapenem in Participants With Complicated Urinary Tract InfectionsCompletedPhase 3Tetraphase Pharmaceuticals, Inc.NCT03032510Written as Eravacycline
- Study to Compare TP-434 and Ertapenem in Community-acquired Complicated Intra-abdominal InfectionsCompletedPhase 2Tetraphase Pharmaceuticals, Inc.NCT01265784Written as TP-434
- A Phase 1, Open-Label Study to Assess the Single-Dose Pharmacokinetics of Eravacycline in Subjects With End Stage Renal Disease and Healthy SubjectsCompletedPhase 1Tetraphase Pharmaceuticals, Inc.NCT02135276Written as eravacycline
- Safety and Pharmacokinetic (PK) Study to Assess Bronchopulmonary Disposition of IV Eravacycline (TP-434) in Healthy Men and WomenCompletedPhase 1Tetraphase Pharmaceuticals, Inc.NCT01989949Written as TP-434 (Eravacycline) reconstituted and administered via an IV infusion
- A Phase 1, Open-Label Study to Assess the Single-Dose Pharmacokinetics of Eravacycline in Subjects With Impaired Hepatic Function and Healthy SubjectsCompletedPhase 1Tetraphase Pharmaceuticals, Inc.NCT02135302Written as eravacycline
- A Safety and PK Study of IV EravacyclineCompletedPhase 1Tetraphase Pharmaceuticals, Inc.NCT03696550Written as Eravacycline (TP-434)
Codes
What other systems call eravacycline · ClinicalTrials.gg INT006022
- MeSH (NLM) C571179eravacyclineOne source NLM
- UNII (FDA) 07896928ZCERAVACYCLINEConfirmed FDA, NLM, Wikidata
- RxNorm 2055906One source FDA
- Wikidata Q15410941eravacyclineConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C171907EravacyclineOne source FDA
- DrugBank DB12329One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C571179 | eravacycline | One source NLM |
| UNII (FDA) | 07896928ZC | ERAVACYCLINE | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2055906 | — | One source FDA |
| Wikidata | Q15410941 | eravacycline | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C171907 | Eravacycline | One source FDA |
| DrugBank | DB12329 | — | One source Wikidata |
Also registered as eravacycline dihydrochloride (UNII WK1NMH89VJ · RxNorm 2055907).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.